Arrakis Therapeutics patents new c-Myc inhibitors

July 15, 2025

Arrakis Therapeutics Inc. has disclosed Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.

Cancer

Incurix describes new c-Myc inhibitors

July 3, 2025

Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.

Cancer

Novel c-Myc inhibitor shows preclinical efficacy and safety in colorectal cancer xenografts

Dec. 1, 2022

Investigators at West China Hospital, Sichuan University and affiliated organizations have discovered a novel c-Myc inhibitor being developed as a potential anticancer agent.

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...